Zenda Technologies is developing technology for the early diagnosis of patients with mild cognitive impairment, a forerunner of Alzheimer’s disease. Its lead technology, DETECT, is an integrated hardware/software platform that provides an isolated immersive environment for rapid cognitive assessment. A series of abbreviated neuropsychological tests are administered through a headset, with the results compared to previous tests and a national database.

Nature of GRA support: Zenda Technologies is a GRA VentureLab graduate, based on the collaborative research of Dr. Michelle LaPlaca at Georgia Tech and Dr. David Wright at the Emory University School of Medicine.